PMID- 24660868
OWN - NLM
STAT- MEDLINE
DCOM- 20150420
LR  - 20231121
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 93
IP  - 3
DP  - 2014 Sep
TI  - Experts' considerations on HLA-haploidentical stem cell transplantation.
PG  - 187-97
LID - 10.1111/ejh.12322 [doi]
AB  - Recently, novel strategies to control graft-versus-host disease and facilitate 
      engraftment have allowed an increasing number of human leukocyte antigen 
      (HLA)-haploidentical hematopoietic stem cell transplantation (haploHSCT) to be 
      performed. A meeting was convened to review the biological rationale and the 
      clinical results of various T-cell-depleted (TCD) and T-cell-replete (TCR) 
      HLA-haploidentical 'transplant platforms'. The objective of the meeting was to 
      promote discussion and consent among leading researchers in the field on three 
      main crucial issues for haploHSCT: (i) eligibility criteria, (ii) choice of the 
      most suitable donor, and (iii) choice of the most appropriate transplant 
      platform. The experts in attendance agreed that a patient who is eligible for an 
      allogeneic transplant and lacks an HLA-identical sibling or an HLA-matched 
      unrelated donor should be considered for an alternative donor transplant. 
      Together with the experience of the individual center, the most important 
      decision criteria in choosing an alternative donor source should be the rapidity 
      of transplantation so as to avoid disease relapse/progression. The choice of the 
      mismatched donor should be driven by younger age, ABO blood group compatibility, 
      and Cytomegalovirus status. If a TCD transplant is planned, NK-alloreactive 
      donors and/or the mother should be preferred. Prospective comparative studies are 
      needed to establish the relative efficacy of different transplant platforms. 
      However, expertise in stem cell manipulation and in adoptive immunotherapy is 
      essential if a TCD transplant platform is chosen.
CI  - (c) 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Patriarca, Francesca
AU  - Patriarca F
AD  - Department of Hematology, Stem Cell Transplant Unit, DISM, University Hospital, 
      Udine, Italy.
FAU - Luznik, Leo
AU  - Luznik L
FAU - Medeot, Marta
AU  - Medeot M
FAU - Zecca, Marco
AU  - Zecca M
FAU - Bacigalupo, Andrea
AU  - Bacigalupo A
FAU - Di Bartolomeo, Paolo
AU  - Di Bartolomeo P
FAU - Arcese, William
AU  - Arcese W
FAU - Corradini, Paolo
AU  - Corradini P
FAU - Ciceri, Fabio
AU  - Ciceri F
FAU - Vago, Luca
AU  - Vago L
FAU - Kanakry, Christopher G
AU  - Kanakry CG
FAU - Fleischhauer, Katharina
AU  - Fleischhauer K
FAU - Martelli, Massimo F
AU  - Martelli MF
FAU - Bosi, Alberto
AU  - Bosi A
FAU - Rambaldi, Alessandro
AU  - Rambaldi A
FAU - Cesaro, Simone
AU  - Cesaro S
FAU - Russo, Domenico
AU  - Russo D
FAU - Fanin, Renato
AU  - Fanin R
LA  - eng
GR  - T32 HL007525/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20140426
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (ABO Blood-Group System)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Myeloablative Agonists)
SB  - IM
MH  - ABO Blood-Group System/immunology
MH  - Congresses as Topic
MH  - Cytomegalovirus Infections/diagnosis
MH  - Graft vs Host Disease/immunology/pathology/*prevention & control
MH  - HLA Antigens/*immunology
MH  - Hematologic Neoplasms/immunology/pathology/*therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Immunotherapy, Adoptive
MH  - Lymphocyte Depletion
MH  - Myeloablative Agonists/*therapeutic use
MH  - Patient Selection
MH  - Time Factors
MH  - *Transplantation Conditioning
MH  - Transplantation, Homologous
MH  - Unrelated Donors
OTO - NOTNLM
OT  - HLA-haploidentical donors
OT  - T-cell depletion
OT  - allogeneic stem cell transplantation
OT  - post-transplantation cyclophosphamide
EDAT- 2014/03/26 06:00
MHDA- 2015/04/22 06:00
CRDT- 2014/03/26 06:00
PHST- 2014/02/24 00:00 [accepted]
PHST- 2014/03/26 06:00 [entrez]
PHST- 2014/03/26 06:00 [pubmed]
PHST- 2015/04/22 06:00 [medline]
AID - 10.1111/ejh.12322 [doi]
PST - ppublish
SO  - Eur J Haematol. 2014 Sep;93(3):187-97. doi: 10.1111/ejh.12322. Epub 2014 Apr 26.